Investopedia: Teva Likely To Tread Water Ahead Of New Strategy

It is perhaps a little ironic that generics giant Teva Pharmaceutical (NYSE:TEVA) finds itself in a position similar to what it helped create for many other pharmaceutical companies over the years. The company is facing increasing competition for its blockbuster MS drug Copaxone, while also having to deal with more pushback on pricing and a thinning pipeline for major generic releases. While Teva does have to face up to some near-term challenges, success with biosimiliars and a decision from management to double-down on internal efficiency and profitability would likely go a long way toward improving investor sentiment.

Please click here for more:
http://www.investopedia.com/stock-analysis/2012/Teva-Likely-To-Tread-Water-Ahead-Of-New-Strategy-TEVA-MYL-PFE-SNY1105.aspx